Related Experiment Video
Updated: Nov 2, 2025
09:08
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
2.0K
gp130 blockade to NOD off Crohn's disease
Tapas Mukherjee1, Dana J Philpott1
1Department of Immunology, Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
Trends in Immunology
|June 9, 2021
Summary
Researchers identified inflammatory cells and a gp130-STAT3 pathway in Crohn's disease (CD) patients refractory to anti-TNF therapy. Targeting this pathway could be a new therapeutic strategy for CD, potentially combined with current treatments.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Crohn's disease (CD) is a chronic inflammatory bowel disease.
- Current anti-TNF therapies are not effective for all patients.
- Understanding the molecular mechanisms driving CD pathogenesis is crucial.
Purpose of the Study:
- To identify specific inflammatory cell populations in CD.
- To investigate the role of the gp130-STAT3 signaling axis in anti-TNF refractory CD.
- To explore potential new therapeutic targets for CD.
Main Methods:
- Analysis of inflammatory cell populations in CD patient samples.
- Investigation of the gp130-STAT3 signaling pathway.
- Correlation of cellular and molecular findings with treatment response.
Main Results:
- Specific inflammatory cell subsets were associated with CD pathogenesis.
- The gp130-STAT3 signaling axis was found to be linked to disease in patients refractory to anti-TNF therapy.
- These findings suggest a potential therapeutic target.
Conclusions:
- gp130-STAT3 signaling is implicated in refractory CD.
- Targeting gp130 may offer a novel therapeutic strategy for CD.
- Combination therapy with anti-TNF agents could be beneficial.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272
01:29Inflammatory Bowel Disease IV: Pharmacological Management
254
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
254
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
258
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
258
01:30Inflammatory Bowel Disease II: Crohn's Disease
500
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
500
01:29Drugs for Treatment of Ulcerative Colitis in IBD
284
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
284